2023-04-25-Locust_Walk-全球生物医药投资趋势_Q1_2023_71页_2mb

Summary of Q1 2023 Biopharma Transactions Report

Core Content

This report provides an overview of the biopharma transaction landscape in Q1 2023, highlighting trends in M&A, strategic partnerships, IPOs, and venture financing. It outlines the ongoing challenges in the industry, including the impact of interest rate hikes, reduced public valuations, and a shift in investment focus towards more de-risked assets.

Main Points

Global Trends

• The first quarter of 2023 continued the trends from 2022, compounded by a systemic shock from the collapse of SVB.
• SVB's failure reflects the industry's ongoing struggle with the aftermath of low interest rate policies and the transition to inflation control.
• Structural changes such as interest rate normalization, industry consolidation, and a reset in public and private valuations are necessary for a sustained recovery.

Market Dynamics

• The number of biotech companies trading below cash reached an all-time high, indicating negative public market sentiment.
• The public market hurdle remains high, with companies focusing on de-risked clinical programs and those with compelling market profiles.
• The IPO market saw strong demand for companies with advanced clinical programs, but post-offering stock performance was volatile.

Venture Financing

• The aggregate deal value for US biopharma venture financing in Q1 2023 was the lowest in over 3 years.
• Series C and later stage companies relied heavily on existing investors due to the unavailability of public market exits.
• New investor participation in later stage rounds was at a new low, signaling a continued weakness in crossover rounds.

Strategic Partnerships

• Strategic partnerships shifted towards earlier stage and oncology-focused companies.
• Early-stage programs dominated high-value partnering activities, with five of the six largest deals targeting oncology assets.
• Biologics dominated the M&A market in Q1, reflecting a preference for mature, less risky assets.

M&A Activity

• M&A dealmaking was robust, driven by the Pfizer + Seagen deal, which was the largest deal of the year.
• Approved assets were the focus of most M&A transactions, indicating a preference for lower technical and regulatory risk.
• M&A equity premiums declined, with the average premium at 39%, showing a shift in valuation expectations.

Key Takeaways

• Public Market Sentiment: Negative and persistent, with many companies trading below cash and reduced IPO activity.
• Interest Rates: Remain a significant challenge, with the potential for a recovery dependent on rate normalization.
• Venture Financing: Struggles with reduced deal values, particularly for later stage companies, due to limited public market access.
• Strategic Partnerships: Increasing interest in early-stage and oncology-focused assets, with biologics being the preferred modality.
• M&A Activity: Continued focus on approved and marketed assets, with a notable decline in equity premiums, suggesting a more cautious market environment.
• Clinical Advancements: Positive readouts in oncology and other therapeutic areas indicate the industry's ongoing progress and potential for new approvals.

Document Structure

Quarter Comments

• Global: Continued challenges from 2022, with SVB's failure as a systemic shock.
• Europe: Not explicitly detailed, but included in the table of contents.
• Asia: Not explicitly detailed, but included in the table of contents.
• About Locust Walk: A global investment bank that supports biopharma companies through strategic transactions and capital raising.

Data Highlights

• XBI Performance: The XBI dropped 32% over the last year, despite several large M&A transactions.
• IPO Performance: Several large IPOs were announced, but post-offering stock performance was mixed.
• Reverse Mergers: Two completed and one announced in Q1, indicating a trend towards alternative financing methods.

Clinical Trial Readouts

• Positive Results: Several positive outcomes were reported in oncology, including for Talzenna + Xtandi and Keytruda in endometrial cancer.
• Other Therapeutic Areas: Positive readouts in hemophilia, myelodysplastic syndrome, and NSCLC were also noted.

Conclusion

The biopharma industry is navigating a complex landscape shaped by macroeconomic factors, reduced public market valuations, and a focus on de-risked assets. While there are signs of structural changes, the market remains challenging, with companies needing to adapt to new financing and transaction environments to achieve success.